Cost Utility of Screening for Barrett’s Esophagus With Esophageal Capsule Endoscopy Versus Conventional Upper Endoscopy  Joel H. Rubenstein, John M. Inadomi, Joel V. Brill, Glenn M. Eisen  Clinical Gastroenterology and Hepatology  Volume 5, Issue 3, Pages 312-318 (March 2007) DOI: 10.1016/j.cgh.2006.12.008 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Schematic of development of EAC. Health states are represented by ovals, and transitions between health states are represented by arrows. Clinical Gastroenterology and Hepatology 2007 5, 312-318DOI: (10.1016/j.cgh.2006.12.008) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 Cost-utility plot under base-case assumptions. The x-axis represents QALYs accrued over the remaining life, and the y-axis represents direct medical costs accrued over the remaining life. EGD screening is cost-effective compared with no screening because the ICER (represented by the slope of the line between the 2 strategies) is $11,254 per QALY gained. Capsule screening is more expensive than EGD and produces fewer QALYs, a condition called dominance. Therefore, EGD is optimal. Clinical Gastroenterology and Hepatology 2007 5, 312-318DOI: (10.1016/j.cgh.2006.12.008) Copyright © 2007 AGA Institute Terms and Conditions